Sarepta Therapeutics (SRPT) downgraded by RBC Capital amid growing uncertainty over Elevidys gene therapy and regulatory concerns.
https://seekingalpha.com/news/4426976-sarepta-downgraded-at-rbc-capital-on-gene-therapy-concerns
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.